Patent 9422368 was granted and assigned to Novo Nordisk on August, 2016 by the United States Patent and Trademark Office.
The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.